Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation.

American journal of kidney diseases : the official journal of the National Kidney Foundation - 1 May 2000

Deighan C J, Caslake M J, McConnell M, Boulton-Jones J M, Packard C J

Abstract excerpt

End-stage renal failure (ESRF) is associated with dyslipidemia and accelerated atherosclerosis. Triglyceride-rich lipoproteins accumulate and qualitative changes take place in low-density lipoprotein (LDL), with a predominance of the small dense LDL phenotype. Increased small dense LDL (LDLIII) is a known risk factor for cardiovascular disease. To assess the extent of LDLIII formation in ESRF and identify factors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Kidney Failure, Chronic
Share to Lipoproteins, LDL

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lipoproteins, VLDL

Share to Phenotype

Share to Renal Dialysis

Source

Identifiers

PMID: 10793019
DOI: 10.1016/s0272-6386(00)70255-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation.PMID 10793019Read ↗

The atherogenic lipoprotein phenotype in renal diseaseSemantic proximity Read ↗

Increased atherogenicity of low-density lipoprotein in heavy proteinuria.Semantic proximity Read ↗

Metabolic origins and clinical significance of LDL heterogeneity.Semantic proximity Read ↗

Low-density lipoprotein density and atherosclerosis. Unraveling the connection.Semantic proximity Read ↗

LDL size: does it matter?Semantic proximity Read ↗

Ability of non-high-density lipoprotein cholesterol and calculated intermediate-density lipoprotein to identify nontraditional lipoprotein subclass risk factors in dialysis patients.Semantic proximity Read ↗

Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a).Semantic proximity Read ↗

HDL and chronic kidney diseaseSemantic proximity Read ↗

Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease.Semantic proximity Read ↗

The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects.Semantic proximity Read ↗

Smaller low-density lipoprotein size as a possible risk factor for the prevalence of coronary artery diseases in haemodialysis patients: associations of cholesteryl ester transfer protein and the hepatic lipase gene polymorphism with low-density lipoprotein size.Semantic proximity Read ↗

Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.